To check the difference of laser and 2% citric acid solution in prevention of radiotherapy induced xerostomia patient.
- Conditions
- Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
- Registration Number
- CTRI/2023/12/060659
- Lead Sponsor
- SAKSHI BATRA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
i.Histologically proven squamous cell carcinoma of head and neck.
ii.Patients treated with upfront r?adio- therapy or chemo-radiotherapy with curative intent.
iii.Patients of both gender and between 18 years to 70 years of age.
iv.Level I and II neck nodes to be part of the radiotherapy portal.
i. Systemic condition with hyposalivation e.g. DM, End stage renal disease etc.
ii. Autoimmune diseases such as Sjogren Syndrome by established diagnosis criteria.
iii. Infectious diseases
iv. Collagen diseases, as were those with incipient tumors (stage T1 or T2) limited to the larynx, as well as those with trismus (reduced mouth opening capacity) due to surgical sequelae.
v. Already on xerostomic drugs (antiretroviral medications, antihistamines, anticholinergics, antihypertensives, decongestants, narcotic analgesics, tricyclic antidepressants)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Stimulated and unstimulated whole saliva flow rateTimepoint: baeline <br/ ><br>3 week <br/ ><br>end of RT <br/ ><br>3 month of completion of RT
- Secondary Outcome Measures
Name Time Method 11-item modified Xerostomia Inventory-Dutch questionnaire versionTimepoint: before therapy and end of the therapy